NASDAQ:INBX Inhibrx Biosciences Q1 2026 Earnings Results & Report $88.96 -1.55 (-1.71%) As of 12:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Inhibrx Biosciences missed analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$2.15 versus the -$1.6750 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeBefore Market OpensConference Call7:00 AM ET Inhibrx Biosciences EPS ResultsActual EPS-$2.15Consensus EPS -$1.6750Beat/MissMissed by -$0.4750One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersInhibrx Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsInhibrx Biosciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Inhibrx Biosciences Q1 2026 Earnings FAQ Did Inhibrx Biosciences beat earnings estimates for Q1 2026? Inhibrx Biosciences (NASDAQ:INBX) reported earnings of -$2.15 per share for Q1 2026, missing the consensus estimate of -$1.6750. The report was announced on Thursday, May 14, 2026. When is Inhibrx Biosciences' next earnings date? Inhibrx Biosciences' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Inhibrx Biosciences on the company's earnings history page. Inhibrx Biosciences Earnings HeadlinesAre Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?October 14 at 12:41 AM | finance.yahoo.comInhibrx Announces Participation in Upcoming Scientific ConferencesOctober 13 at 4:00 PM | prnewswire.comThis Tiny Sub-$1 Gold-Silver Royalty Stock Is Ready to RunA gold-silver royalty firm just closed the largest transaction in its history a new gold streaming deal on a producing mine. The company earns cash flow without operating a single mine, and shares still trade below $1. A major mining financier has already invested and joins the CEO in an exclusive interview.October 16 at 1:00 AM | Digest Publishing (Ad)Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp ReratingSeptember 29, 2026 | finance.yahoo.comInhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?September 24, 2026 | uk.finance.yahoo.comInhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?September 15, 2026 | fool.comSee More Inhibrx Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx Biosciences and other key companies, straight to your email. Email Address About Inhibrx BiosciencesInhibrx Biosciences (NASDAQ:INBX) is a biotechnology company focused on discovering and developing engineered biologic medicines for serious diseases with limited treatment options. The company’s platform has been used to create multifunctional proteins and antibody-based therapies designed to address targets that may be difficult to treat with conventional drugs. Its leading program was INBRX-101, an engineered recombinant human alpha-1 antitrypsin therapy developed for patients with alpha-1 antitrypsin deficiency-associated lung disease. Inhibrx also advanced additional investigational therapies, including INBRX-109, an antibody-based treatment candidate studied in oncology. These products have been evaluated through clinical development programs rather than commercialized as approved medicines by the company. Inhibrx was founded in 2010 and was based in La Jolla, California. In 2024, Sanofi completed its acquisition of Inhibrx, gaining rights to the company’s principal programs, including INBRX-101. The company’s development activities and clinical programs have been directed primarily toward patients in the United States and other international markets through global research and clinical-trial efforts.View Inhibrx Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Morgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure3 Stocks to Watch as Wall Street Wealth Fuels Consumer Spending Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
